Industry News

23 February 2026

Sai Life Sciences Plans to Hire 700+ Professionals in FY27 Amid Growth Surge

Sai Life Sciences Limited has announced an ambitious recruitment drive to hire more than 700 scientific, technical and management professionals in the 2026–27 financial year as it scales up operations to meet growing global demand for drug discovery, development and manufacturing services.

23 February 2026

Gilead Sciences Moves to Acquire Arcellx in USD 7.8B Deal to Fully Harness Anito-cel Potential

Gilead Sciences today announced a definitive agreement to acquire Arcellx in a transaction valued at approximately USD 7.8 billion, marking a major step in Gilead’s expansion in next-generation cell therapy.

23 February 2026

European Commission Clears Ranluspec®, Strengthening Sandoz’s Ophthalmology Biosimilars Portfolio

Sandoz has announced that the European Commission has granted marketing authorization for Ranluspec® (ranibizumab), a biosimilar developed by Lupin. The approval marks a significant step in expanding access to advanced ophthalmic therapies across Europe.

17 February 2026

Lupin Expands Canada Specialty Portfolio with Spektus Deal for DeslaFlex

Global pharmaceutical company Lupin Limited has entered into a licensing and supply agreement with Spektus Pharma to commercialize DeslaFlex in Canada, marking a strategic move to strengthen its central nervous system (CNS) portfolio in the region.

17 February 2026

Lilly Eyes India as Strategic Export Base as Mounjaro Demand Surges

Eli Lilly and Company is strengthening its presence in India and evaluating the country as a strategic export base amid rising demand for its blockbuster diabetes and weight-loss therapy Mounjaro, as reported by Reuters.

12 February 2026

SEC Seeks Protocol Changes in Zydus Phase III Trial for MMR Vaccine

The Subject Expert Committee (SEC) on Vaccines has asked Zydus Lifesciences Ltd. to revise its Phase III clinical trial protocol for its Measles, Mumps and Rubella (MMR) Vaccine (Live) I.P. (Freeze Dried). The meeting was held on 29 January 2026 in hybrid mode to review biological and PAC proposals and to advise the Drugs Controller General (India).

12 February 2026

Zydus Lifesciences Reports 30% Revenue Growth in Q3 FY26

Zydus Lifesciences Limited has reported strong financial results for the third quarter and nine months ended December 31, 2025. The company’s revenue for Q3 FY26 stood at Rs. 68,645 million, showing a growth of 30% compared to the same period last year.

10 February 2026

Novo Nordisk Sues Hims & Hers Over Unsafe Knock-Off Wegovy and Ozempic Products

Novo Nordisk has launched legal action against US telehealth company Hims & Hers, accusing it of unlawfully marketing unapproved and potentially unsafe compounded versions of its bestselling GLP-1 medicines Wegovy® and Ozempic®.

10 February 2026

Lupin, Astellas Settle Mirabegron Patent Dispute for USD 90 Million

Lupin Limited has reached a settlement and licensing agreement with Astellas Pharma and its group companies, bringing an end to the long-running patent infringement litigation related to the overactive bladder drug Mirabegron (marketed by Astellas as Myrbetriq).

Lupin said the agreement was signed by the company and its wholly owned US subsidiary, Lupin Pharmaceuticals, Inc., with Astellas Pharma, Inc., Astellas Ireland Co., Ltd., and Astellas Pharma Global Development, Inc.

6 February 2026

Alembic Pharma Wins USFDA Nod for Parkinson Combination Therapy Tablets

Alembic Pharmaceuticals Limited has strengthened its US generics portfolio with the final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) covering Carbidopa, Levodopa and Entacapone Tablets.

Search

Sai Life Sciences Plans to Hire 700+ Professionals in FY27 Amid Growth Surge

RECOMMENDED POSTS

Subscribe with us

Jobs by Category